Eeva Frequently Asked Questions
Auxogyn received CE mark approval to market Eeva in the EU in July 2012. Eeva is currently approved and available for use only in the EU. It is not yet cleared in the United States and is limited to investigational use only.
> What is the EEVA™ Test?
Eeva stands for Early Embryo Viability Assessment Test, a non-invasive test that helps embryologists identify on Day 3 which embryos are most likely to advance to the blastocyst stage, a critical milestone in embryo development. Eeva consists of a special microscope that fits inside a standard incubator and takes video of your embryos, which are analysed by proprietary, intelligent software. The Eeva Test enables embryologists to more confidently select the best embryos for transfer back to your womb using objective information not otherwise available through traditional embryo grading techniques.
> What does Eeva do?
Eeva provides embryologists the capability to automatically evaluate, on Day 3, an embryo’s ability to develop into a blastocyst, a critical milestone in the embryo’s development. Using automatic image capture, Eeva tracks each embryo as it develops from a single-cell embryo into the two-cell, three-cell and four cell stages. On Day 3, Eeva calculates the time it took each embryo to achieve each cell-division milestone and uses its proprietary algorithm to predict which embryos are most likely viable. Your IVF team can combine the quantitative information provided by the Eeva Test with traditional embryo morphology when making the decision regarding embryo transfer and your IVF treatment pathway.
> Is Eeva safe?
Eeva is safe and non-invasive. Research has shown that imaging embryos has no detrimental effects on embryo development.
> What information can patients receive from an Eeva Test?
At the discretion of your IVF team, you may receive Eeva images, videos and reports.
> How will I know if Eeva can help improve my IVF cycle?
Talk to your IVF team to explore whether Eeva could be helpful for you.
> Where is the Eeva IVF test available?
Auxogyn received CE mark approval to market Eeva in the EU in July 2012. Eeva is currently approved and available for use only in the EU. Please see the clinic finder to find the closest clinic with Eeva. In addition, Auxogyn completed a multi-center prospective clinical trial in the United States, designed to validate Eeva. Currently Auxogyn is conducting several studies at select fertility clinics worldwide. For more information regarding the specifics of the study currently enrolling, including specific patient eligibility criteria, please visit ClinicalTrials.gov.
> Who developed Eeva?
Eeva was developed by Auxogyn. The underlying science is based on landmark research by a team of scientists from Stanford University who recognised the first link between embryo developmental outcome, cell division timings and the molecular health of the embryo. The research was published in the highly regarded scientific journal Nature Biotechnology (October 2010) and measured the time it took each embryo to achieve specific cell development milestones during the first two days after fertilisation in vitro. This led to the discovery of precise cell-division timing parameters that could non-invasively predict on Day 3 which embryos were most likely to develop to blastocyst stage on Day 5. Viable embryos were observed to follow specific development timelines. Eeva analyses which embryos follow these specific development timelines to predict which embryos have the highest likelihood of resulting in a successful pregnancy.